Search Results
Dec 09, 2025, 07:30 ET Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
Because severe renal impairment increases pirtobrutinib exposure, reduce Jaypirca dose in these patients according to approved labeling.PT HCP ISI MCL_CLL Q42025Please see
More news about: Eli Lilly and Company
Dec 08, 2025, 09:03 ET New Symptom-Management Guide Offers Practical Support for People Undergoing Metastatic Breast Cancer Treatment
(AONN+), this complimentary Guide is available for U.S. healthcare professionals. Viver's unique methodology utilizes up to date literature and patient and HCP interviews to provide real-world evidence and real-world impact.
More news about: Viver Health
Dec 08, 2025, 09:00 ET Imre taps Ogilvy's Nadine Lafond as CEO to lead bold, new phase of agency evolution
Imre is now a full-service agency-of-record (AOR) supporting an impressive roster of accounts at all stages of the brand life cycle, including both HCP and DTC launches, led by a team of seasoned launch experts. Imre's innovative approaches span across creative, brand strategy, omnichannel marketing,
More news about: Imre
Dec 08, 2025, 07:30 ET Recordati Rare Diseases Showcases Real-World Evidence Studies That Advance Understanding of Castleman Disease (CD) at the American Society of Hematology (ASH) Annual Meeting
a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT.Before starting SYLVANT, tell your healthcare provider (HCP) about all of your medical conditions, including if you:have an infection. You should not receive SYLVANT if you have a severe
More news about: Recordati
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
Because severe renal impairment increases pirtobrutinib exposure, reduce Jaypirca dose in these patients according to approved labeling.PT HCP ISI MCL_CLL Q42025Please see
More news about: Eli Lilly and Company
Dec 05, 2025, 13:14 ET Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications
scientific, educational, and engagement expertise, the company serves the life sciences industry and HCP community across three core divisions focused on delivering Accredited Medical Education, HCP Insights, and Medical Communications—all in service of improving patient care and accelerating clinical
More news about: Decera Clinical
Dec 05, 2025, 11:00 ET Vaniam Group Launches Predictive Pathways: A New Capability for Anticipating Market-Shaping Signals
Predictive Pathways analyzes converging signals across publications, HCP discussions, congress activity, competitive movement, and external market indicators to surface early directional shifts, often within days of a major
More news about: Vaniam Group LLC
Dec 03, 2025, 12:59 ET U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Because severe renal impairment increases pirtobrutinib exposure, reduce Jaypirca dose in these patients according to approved labeling.PT HCP ISI MCL_CLL Q42025Please see
More news about: Eli Lilly and Company
Dec 02, 2025, 09:00 ET Impiricus Named the Fastest-Growing Company in North America on Deloitte's 2025 Technology Fast 500™
Impiricus, the AI-powered Healthcare Provider (HCP) Engagement Engine, has been ranked No. 1 overall on the
More news about: Impiricus
Nov 24, 2025, 16:30 ET Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
Prescribing Information for Inluriyo. IN HCP ISI M APPAbout Verzenio (abemaciclib) Verzenio (abemaciclib) is approved to treat people with certain HR+, HER2- breast cancers
More news about: Eli Lilly and Company
Nov 24, 2025, 12:00 ET Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
impairment increases pirtobrutinib exposure. Reduce Jaypirca dosage in patients with severe renal impairment according to approved labeling. PT HCP ISI MCL_CLL AA JUN2024Please see
More news about: Eli Lilly and Company
Nov 24, 2025, 11:58 ET Enquyst Technologies Demonstrates First-in-Class, Chromatography-free Downstream Processing of a Monoclonal Antibody (mAb) with its Patented Isoelectric Point Purification (IPP) Technology Platform and Announces Receipt of a National Institute for Innovation in Manufacturing Biopharmaceutical (NIIMBL) Led Gates Grand Challenge Program Award
biosimilar, Enquyst was able to demonstrate that its IPP technology platform was able to meet or exceed results in the removal of Host Cell Protein (HCP) and Host Cell DNA (HC DNA) impurities, while increasing product yield. With further optimization of its IPP technology platform, Enquyst believes it
More news about: Enquyst Technologies
Nov 21, 2025, 09:00 ET Sorcero Secures $42.5M Series B Financing Led by NewSpring Capital to Scale Its AI Platform, Accelerate Expansion Across Life Sciences
70% of healthcare professionals (HCP) believe that pharma representatives don't understand their needs and
More news about: Sorcero
Nov 21, 2025, 08:37 ET Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
platform analyzes large volumes of data, enabling companies to continuously and consistently automate key commercial functions such as healthcare provider (HCP) targeting, precision forecasting, omnichannel engagement, and patient identification.Trusted by Fortune 500 pharmaceutical companies around the
More news about: Citius Oncology, Inc.
Nov 19, 2025, 21:53 ET Health Union Recognized for Unmatched Excellence in HCP and Patient Engagement, Earning 19 Awards
include: Gold Digital Health Award: Physician/Clinical Portal for HCP Connect: Myasthenia Gravis at
More news about: Health Union
Nov 19, 2025, 09:56 ET ODAIA Adds Senior Pharma and AI Leaders to Accelerate Growth and Industry Adoption
analyzes customer data to provide predictive insights that help commercial teams optimize go-to-market strategies and prioritize timely and relevant HCP engagements. With advanced capabilities in
More news about: odaia
Nov 19, 2025, 05:00 ET Deloitte Unveils 2025 North America Technology Fast 500™ Rankings
rankings." Impiricus claimed the top spot with a growth rate of 29,738% from 2021 to 2024. With its AI-powered Healthcare Professional (HCP) Engagement Engine, Impiricus was created to ethically connect physicians to pharmaceutical resources and accelerate patient access to life-saving
More news about: Deloitte LLP
Nov 18, 2025, 08:52 ET Precision AQ Invests in Phluence to Advance Next Generation of Agentic Patient Solutions
Phluence (formerly Lifelink Systems), an advanced agentic workflow management platform designed to virtualize patient and HCP engagement. By integrating best-in-class generative AI models and toolkits, Phluence enables pharmaceutical manufacturers to modernize patient services
More news about: Precision AQ
Nov 18, 2025, 08:50 ET Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
biologics today. The increased concentration reduces the volume of injection for the same dosage and will create more opportunities for at-home and HCP office delivery, including via small volume auto-injector or with Halozyme's innovative high volume auto-injector. Halozyme has
More news about: Halozyme Therapeutics, Inc.
Nov 13, 2025, 09:00 ET Impiricus Launches Ascend, An AI Platform To Ethically Connect Physicians And Pharma
access to the needed treatments. Built on Impiricus' proprietary AI models trained on over four billion healthcare professional (HCP) data points and interactions, Ascend leverages a unique, agentic AI delivery platform that extends beyond the capabilities of basic chatbots. Ascend
More news about: Impiricus
Nov 13, 2025, 07:01 ET Housecall Pro announces Winter Summit 2025, featuring Emmy-winning host Mike Rowe
https://housecallpro.registration.goldcast.io/events/db19e608-2a52-40c6-bd74-2ac1fdd613ba?utm_source=Media&utm_medium=Press-release&utm_campaign=hcp_virtual_winter_summit. For more information about Housecall
More news about: Housecall Pro
Nov 10, 2025, 09:08 ET The Inception Company and Data360 Announce Strategic Partnership to Transform HCP Engagement Through Dynamic Digital Events
and proven identity and intent data with the most trusted HCP virtual event experience in the industry," said James J. Miller, Jr., President and CEO of Data360. "Inception's dynamic event model pairs expertly with Data360's verified HCP audiences and behavioral triggers, delivering the right message
More news about: The Inception Company
Nov 05, 2025, 13:38 ET ACTO STELLT ACTOVERSE VOR: EIN MARKTPLATZ FÜR PARTNERLÖSUNGEN ZUR FÖRDERUNG VON INNOVATION UND EFFIZIENZ IM BEREICH EXZELLENZ AUF DEM VEEVA COMMERCIAL SUMMIT EUROPE
Produkteinführungen, Rollenspiele und Zertifizierungen vorzubereiten. Datenpartner bieten Marktforschung, HCP-Profiling und Daten zur Patientenerfahrung, die Einblicke liefern, um die Lern- und Praxiserfahrungen des Außendienstteams zu personalisieren.
More news about: ACTO Technologies, Inc.
Nov 05, 2025, 08:30 ET ACTO UNVEILS ACTOVERSE: A PARTNER SOLUTIONS MARKETPLACE DRIVING INNOVATION AND EFFICIENCY IN FIELD EXCELLENCE AT VEEVA COMMERCIAL SUMMIT EUROPE
roleplay, and certification with speed and confidence. Data Partners provides market research, HCP profiling, and patient journey data that provides insight to help personalize the field team's learning and practice experience.
More news about: ACTO Technologies, Inc.
Nov 05, 2025, 02:30 ET ACTO UNVEILS ACTOVERSE: A PARTNER SOLUTIONS MARKETPLACE DRIVING INNOVATION AND EFFICIENCY IN FIELD EXCELLENCE AT VEEVA COMMERCIAL SUMMIT EUROPE
roleplay, and certification with speed and confidence. Data Partners provides market research, HCP profiling, and patient journey data that provides insight to help personalize the field team's learning and practice experience.
More news about: ACTO Technologies, Inc.